Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE vs ANDROID 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Testosterone cypionate is a prodrug of testosterone, which binds to androgen receptors and modulates gene expression, promoting male secondary sex characteristics and anabolic effects. Estradiol cypionate is a prodrug of estradiol, which binds to estrogen receptors and regulates gene transcription involved in female reproductive development and maintenance.
Android 25 contains methyltestosterone, a synthetic androgen that binds to androgen receptors, promoting protein synthesis and anabolic effects. It also inhibits gonadotropin secretion from the pituitary, reducing endogenous testosterone production.
Moderate to severe vasomotor symptoms due to menopause (estradiol component, off-label for testosterone),Male hypogonadism (testosterone component)
Hypogonadism in males (primary and secondary),Delayed puberty in males,Metastatic breast cancer in women (as palliative therapy)
Testosterone cypionate 50-200 mg and estradiol cypionate 2-10 mg intramuscularly every 2-4 weeks.
Testosterone 25 mg subcutaneously or intramuscularly every 2 to 4 weeks. Alternatively, 125 mg intramuscularly every 10 days.
Testosterone cypionate: approximately 8 days; estradiol cypionate: approximately 8-10 days. Clinical context: steady-state reached in 3-5 weeks.
Terminal elimination half-life: 10–100 minutes (testosterone); clinical context: rapid clearance necessitates frequent dosing or use of esters for sustained effect
Testosterone cypionate: Hydrolyzed to testosterone then metabolized primarily in the liver via oxidation (CYP3A4, CYP2C9) and conjugation; estradiol cypionate: Hydrolyzed to estradiol then metabolized via hydroxylation (CYP1A2, CYP3A4) and glucuronidation.
Primarily hepatic via reduction and oxidation; metabolites include androsterone and etiocholanolone; excreted in urine.
Renal (90% as glucuronide and sulfate conjugates, less than 5% as unchanged drug); fecal (approximately 10%).
Renal: 90% (as glucuronide and sulfate conjugates, 5–10% unchanged); fecal/biliary: 10%
Testosterone: 97-99% bound to sex hormone-binding globulin (SHBG) and albumin; estradiol: 98% bound to SHBG and albumin.
97–99% (sex hormone-binding globulin and albumin)
Testosterone: approximately 0.6 L/kg; estradiol: approximately 0.5 L/kg. Indicates distribution into peripheral tissues.
0.3–0.6 L/kg; indicates distribution into lean muscle and sex organs
Intramuscular: approximately 100% due to slow release from oil depot; no oral bioavailability (hepatic first-pass inactivation).
Oral: <5% (methyltestosterone: ~20–25% due to 17α-alkylation); IM: 100%
No specific dose adjustment recommended; use with caution in severe impairment due to limited data.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, consider reducing dose or increasing interval; monitor for fluid retention and hypertension.
Contraindicated in severe hepatic impairment (Child-Pugh C). For mild to moderate (Child-Pugh A or B), use with caution and monitor hepatic function.
Contraindicated in Child-Pugh class B or C cirrhosis. For mild hepatic impairment (Child-Pugh A), start with lower dose (e.g., 12.5 mg every 2 weeks) and titrate based on response and liver function.
Not recommended for pediatric use; safety and efficacy not established.
Not recommended for use in pediatric patients (safety and efficacy not established). For male adolescents with hypogonadism, individualize: start at 12.5 mg every 2 weeks and adjust based on testosterone levels and growth.
Use lower end of dosing range (e.g., testosterone cypionate 50-100 mg with estradiol cypionate 2-5 mg every 4 weeks) due to increased risk of cardiovascular and prostate adverse effects; monitor closely.
Start with lower initial dose (e.g., 12.5 mg every 2 weeks); monitor prostate-specific antigen (PSA) and hematocrit frequently. Avoid in patients with prostate cancer or untreated sleep apnea.
Estrogens, with or without progestins, should not be used for the prevention of cardiovascular disease or dementia. Increased risks of endometrial cancer, stroke, and deep vein thrombosis. Venous thromboembolism risk is increased with estrogen-containing products.
WARNING: Androgens are contraindicated in pregnancy due to masculinization of female fetus. Hepatotoxicity, including peliosis hepatis and hepatic neoplasms, has been reported with prolonged use.
Cardiovascular risk: increased risk of myocardial infarction, stroke, venous thromboembolism,Endometrial cancer: unopposed estrogen use increases risk,Breast cancer: caution in patients with known or suspected estrogen-dependent tumors,Hepatic impairment: dose adjustment may be needed,Hypercalcemia: caution in patients with bone metastases,Fluid retention: caution in cardiac or renal dysfunction
Use with caution in patients with hepatic, renal, or cardiovascular disease; may cause gynecomastia, edema, hypercalcemia, and polycythemia; monitor liver function, lipid profile, and hematocrit periodically; may accelerate bone maturation in children; risk of prostate hypertrophy and urethral obstruction.
Pregnancy (estrogen component),Breast cancer (known, suspected, or history, unless appropriate indication),Estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Active thromboembolic disease or history of thromboembolism (e.g., DVT, PE),Known hypersensitivity to components,Men with prostate or breast cancer (testosterone component)
Known or suspected prostate cancer; male breast cancer; pregnancy; lactation; hypersensitivity to methyltestosterone; severe hepatic impairment.
Avoid excessive grapefruit juice as it may affect hormone metabolism. No specific food interactions; maintain a balanced diet.
Take with food containing fat (e.g., avocado, nuts, olive oil) to enhance absorption. Avoid grapefruit juice as it may increase testosterone levels via CYP3A4 inhibition. Limit alcohol due to potential liver effects.
First trimester: High risk of masculinization of female fetus. Second trimester: Androgenic effects may cause clitoral enlargement, labial fusion, and urogenital sinus abnormalities. Third trimester: Possible advanced bone age and growth acceleration. Not recommended in any trimester.
Android 25 (methyltestosterone) is an androgen. First trimester: Virilization of female fetus, including clitoromegaly, labial fusion, urogenital sinus abnormalities if exposure occurs before 12 weeks gestation. Second and third trimesters: Continued risk of female pseudohermaphroditism, and potential for masculinization of female external genitalia. Androgens can cross the placenta and may also cause skeletal abnormalities and growth retardation. Pregnancy category X.
Contraindicated during breast-feeding. Excreted in breast milk, may cause masculinization of female infant. M/P ratio not known.
Methyltestosterone is excreted into breast milk; M/P ratio not established. May cause virilization in female infants and premature sexual development in male infants. Androgens can suppress lactation. Use during breastfeeding is contraindicated.
Not recommended for use during pregnancy; dose adjustment is not applicable.
Android 25 is contraindicated in pregnancy, so no dosing adjustments are applicable. If used inadvertently, discontinue immediately. No pharmacokinetic data to guide dose changes; avoid use entirely.
Monitor for signs of thromboembolism, especially in patients with risk factors. Measure serum testosterone and estradiol levels periodically to maintain therapeutic range. Use with caution in patients with history of myocardial infarction or stroke. Contraindicated in men with breast or prostate cancer. May cause gynecomastia and fluid retention.
Android 25 (testosterone undecanoate) requires absorption via lymphatic system; administer with fat-containing meal. Monitor serum testosterone levels 3-5 hours post-dose. Avoid in patients with breast cancer or known or suspected prostate cancer. Risk of polycythemia; check hematocrit before and during therapy.
Report any signs of blood clots (leg pain, chest pain, shortness of breath) immediately.,Do not use if you are pregnant or breastfeeding.,Regular blood tests are required to monitor hormone levels and liver function.,Use as prescribed; do not adjust dose without consulting your healthcare provider.,Inform your doctor about all medications you are taking, including over-the-counter drugs.
Take capsules with meals, especially those containing fat, to improve absorption.,Do not chew or crush capsules; swallow whole.,Report signs of deep vein thrombosis (leg swelling, pain) or pulmonary embolism (sudden dyspnea, chest pain).,Women of reproductive potential should avoid pregnancy; use effective contraception.,Keep out of reach of children; testosterone can cause serious harm if accidentally ingested.,Regular blood tests (testosterone, hematocrit, PSA, lipid profile) are required.
"Estradiol (estrogen) may reduce the anticoagulant effect of warfarin, likely by enhancing the synthesis of clotting factors (e.g., factors II, VII, IX, X) in the liver. This interaction can lead to a decrease in the International Normalized Ratio (INR) and potentially increase the risk of thromboembolic events. Conversely, when estradiol is discontinued, warfarin's effect may increase, raising the risk of bleeding."
"Acitretin, a retinoid used for psoriasis, induces CYP3A4 enzymes, accelerating estradiol metabolism and reducing its systemic exposure. This can lead to decreased contraceptive efficacy of estrogen-containing oral contraceptives, potentially resulting in unplanned pregnancy. Additionally, acitretin itself is teratogenic, making effective contraception critical during therapy."
"The combination of Halcinonide, a potent topical corticosteroid, with Estradiol may lead to increased systemic absorption of Estradiol due to corticosteroid-induced inhibition of estrogen metabolism via competition for cytochrome P450 enzymes, particularly CYP3A4. This interaction can result in elevated estradiol serum concentrations, potentially augmenting estrogenic effects such as thromboembolic risk, endometrial hyperplasia, and hormonal imbalance. Clinically, patients may experience symptoms like breakthrough bleeding, breast tenderness, or worsened side effects of estrogen therapy."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE vs ANDROID 25, answered by our medical review team.
TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE is a Androgen that works by Testosterone cypionate is a prodrug of testosterone, which binds to androgen receptors and modulates gene expression, promoting male secondary sex characteristics and anabolic effects. Estradiol cypionate is a prodrug of estradiol, which binds to estrogen receptors and regulates gene transcription involved in female reproductive development and maintenance.. ANDROID 25 is a Androgen that works by Android 25 contains methyltestosterone, a synthetic androgen that binds to androgen receptors, promoting protein synthesis and anabolic effects. It also inhibits gonadotropin secretion from the pituitary, reducing endogenous testosterone production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE and ANDROID 25 depend on the specific clinical indication. These are both Androgen agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE is: Testosterone cypionate 50-200 mg and estradiol cypionate 2-10 mg intramuscularly every 2-4 weeks.. The standard adult dose of ANDROID 25 is: Testosterone 25 mg subcutaneously or intramuscularly every 2 to 4 weeks. Alternatively, 125 mg intramuscularly every 10 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE and ANDROID 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE is classified as Category D/X. First trimester: High risk of masculinization of female fetus. Second trimester: Androgenic effects may cause clitoral enlargement, labial fusion, and urogenital sinus abnormalitie. ANDROID 25 is classified as Category C. Android 25 (methyltestosterone) is an androgen. First trimester: Virilization of female fetus, including clitoromegaly, labial fusion, urogenital sinus abnormalities if exposure oc. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.